ArticleNeuropsychiatric disease and treatment2026
Effect of Venlafaxine on Inflammatory Level in Patients with Depression.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Venlafaxine is widely applied to treat depression. Herein, we further explore the effect of venlafaxine on inflammatory level in patients with depression. Methods: Retrospectively, the medical data of patients (from January 2020 to February 2023, following up for 1 year) with depression (n=134) and without depression (health group, n=63) were collected. According to different treatment methods, patients with depression were categorized into the venlafaxine group (n=71) and the fluoxetine group (n=63). After treatment 8 weeks and 1 year, the baseline characteristics, therapeutic effect, inflammatory level and adverse events were analyzed. Results: After treatment 8 weeks and 1 year, there were significant improvements about depression and inflammatory level in venlafaxine group and fluoxetine group ( Conclusion: In this study, venlafaxine use was associated with improvement in depressive symptoms and correlated with reduced levels of inflammatory markers in patients with depression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.